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The biggest challenge of last year worldwide has 
undoubtedly been to deal with the outbreak of the 
novel coronavirus (SARS -COV-2), which was spread 
from Wuhan, China to other parts of the world at the 
end of last year (2019).  
SARS-COV-2 uses the ACE2 receptor to enter 
human cells and involve these receptors (1). ACE2 is 
capable of cleaving, des-Arg bradykinin which is 
involved locally in vessel dilation through binding to 
the B1 receptor (2). Des-Arg-BK is the only active 
metabolite of BK (3). It should be noted that activation 
of the B1 receptor in lung endothelial cells causes 
severe deterioration and increased mortality in many 
diseases; on the other hand, this receptor on endothelial 
cells is upregulated by proinflammatory cytokines (4). 
Followed local lung angioedema could chip into 
the disease by an increase of local immune cell influx 
and proinflammatory cytokines leading to increasing 
severity (5). This inflammation persuades more B1 
expression, and possibly via antibody-dependent 
increase of viral infection leading to continued ACE2 
dysfunction in the lung because of the durability of the 
virus (6). In this standpoint bradykinin-dependent, 
local lung angioedema via B1 and B2 receptors is a 
significant trait of SARS-COV-2 (7). Hence it seems 
that blocking the B1 and B2 receptors might have an 
ameliorating effect on disease caused by COVID-19. 
Bradykinin is a pro-inflammatory molecule (8). 
Bradykinin B1 and B2 receptors are constitutively 
expressed in the airways on several residential and/or 
immune cells (9). Their expression can also be induced 
by inflammatory mediators, usually associated with 
eosinophil and neutrophil recruitment, such as IL-4, 
IL-13, TNF-α, IL-6, and IL-8, via intracellular MAPK 
and NF-κB signaling (10). BK exerts its 
pharmacological effects, mainly vasodilation, by 
activating constitutively expressed B2 receptors (11). 
BK is metabolized by three metallopeptidases (5). 
Whereas, the angiotensin-converting enzyme (ACE) 
constitutes the main degradation pathway that 
transforms BK into its final inactive metabolite BK. 
Bromelain is an anti-inflammatory that plays a 
role in reducing serum and tissue levels of kininogen 
and bradykinin (12). This substance is obtained from 
raw pineapple extract and if orally administered, while 
retaining its properties, it is reabsorbed through the 
intestines (13). Numerous therapeutic properties of this 
substance are known for many diseases including 
bronchitis, sinusitis, arthritis, and inflammation. The 
positive effects on the mentioned diseases can be 
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attributed to the anti-edema, anti-inflammatory, and 
coagulation-inhibiting properties of bromelain (14). 
These effects are due to an enhancement of the serum 
fibrinolytic activity and inhibition of the fibrinogen 
synthesis, as well as a direct degradation of fibrin and 
fibrinogen (13). As mentioned, bromelain has anti-
inflammatory properties. On the other hand, this drug 
potentially activates the immune system in association 
with the rapid response to cellular stress (15). 
Conversely, bromelain reduces cytokine secretion 
when immune cells are already stimulated in the 
condition of inflammation-induced overproduction of 
cytokines. 
Thus, by carefully studying the pathogenesis 
and clinical signs of patients with SARS -COV-2, the 
use of Bromelain can have a positive effect on the 
treatment process of these patients. However, to 
determine the type of treatment, the amount of 
administration, the duration of action of the drug and 
to determine the possible adverse effects, the 
implementation of a clinical process can play an 
effective role. 
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